Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization.
The third hypervariable region (V3) of the HIV-1 envelope gp120 protein contains the principal neutralizing domain. Most neutralizing antibodies directed toward this region are very type-specific. Conserved sequences do exist within this region, however, and may prove useful in developing vaccines and therapeutic monoclonal antibodies (MABs) capable of targeting diverse HIV-1 isolates. We have used synthetic peptides containing conserved V3 sequences as immunogens to produce a panel of neutralizing MABs. The characterization of these MABs is described here. In addition, a series of in vitro assays has been developed that may be useful in predicting the neutralization potential of individual antibodies.
White-Scharf
M E
ME
Repligen Corporation, Cambridge, Massachusetts 02139.
Potts
B J
BJ
Smith
L M
LM
Sokolowski
K A
KA
Rusche
J R
JR
Silver
S
S
D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000915:Antibody Affinity; D001667:Binding, Competitive; D000939:Epitopes; D015483:HIV Antibodies / Q000276:immunology*; D015488:HIV Antigens / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D051379:Mice; D008815:Mice, Inbred Strains; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D010455:Peptides / Q000276:immunology
D000911:Antibodies, Monoclonal; D000939:Epitopes; D015483:HIV Antibodies; D015488:HIV Antigens; D015699:HIV Envelope Protein gp120; D010455:Peptides